Computational model for effects of ligand/receptor binding properties on interleukin-2 trafficking dynamics and T cell proliferation response

Biotechnology Progress

Volumn 16, Issue 5, 2000, Pages 905-916

  Fallon, E M ^a,b,c   Lauffenburger, D A ^a,b  

^a USA   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROLIFERATION RESPONSE; CYTOKINE RECEPTORS; HETEROTRIMERIC RECEPTOR; INTERLEUKIN TRAFFICKING DYNAMICS;

CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STIMULATION; CYTOKINE; ENDOSOME; HEMATOPOIETIC CELL; INTERLEUKIN RECEPTOR; LIGAND BINDING; MODEL; T LYMPHOCYTE;

BINDING ENERGY; BIOREACTORS; BIOTECHNOLOGY; COMPUTER SIMULATION; CYTOLOGY; ENDOSCOPY; NUMERICAL METHODS; PH EFFECTS;

CELL CULTURE;

BIOLOGICAL TRANSPORT; CELL DIVISION; HUMANS; INTERLEUKIN-2; LIGANDS; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES;

EID: 0034281442     PISSN: 87567938     EISSN: None     Source Type: Journal    
DOI: 10.1021/bp000097t     Document Type: Article

References (88)

1. Lymphocyte responses and cytokines
2. Endocytosis and signals for internalization
3. Physicochemical and biochemical characteristics of glycosylated recombinant human granulocyte colony stimulating factor (lenograstim)
4. Immune-mediated side-effects of cytokines in humans
5. Interleukin-2 and its receptors: Recent advances and new immunological functions
6. Interleukin-2: Inception, impact and implications
7. Ultra-low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies
8. Experiences in immune reconstitution. The rationale for interleukin-2 administration to HIV-infected individuals
9. Interleukin-2 and human immunodeficiency virus infection: Pathogenic mechanisms and potential for immunologic enhancement
10. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus
11. Rational interleukin 2 therapy for HIV positive individuals: Daily low doses enhance immune function without toxicity
12. Aldesleukin (recombinant interleukin-2) - A review of its pharmacological properties, clinical efficacy and tolerability in patients with metastatic melanoma
13. Aldesleukin (recombinant interleukin-2) - A review of its pharmacological properties, clinical efficacy and tolerability in patients with renal cell carcinoma
14. Recombinant interleukin-2 in cancer - Basic and clinical aspects
15. Interleukin-2: A review of its pharmacological properties and therapeutic use in patients with cancer
16. Effects of route and formulation on clinical pharmacokinetics of interleukin-2
17. Lowest dose interleukin-2 immunotherapy
18. Scratching the (cell) surface: Cytokine engineering for improved ligand/receptor trafficking dynamics
19. Structural design and molecular evolution of a cytokine receptor superfamily
20. A new cytokine receptor superfamily
21. Formation of high affinity IL-2 receptors is dependent on a nonligand binding region of the α subunit
22. The role of low-affinity interleukin-2 receptors in autocrine ligand binding: Alternative mechanisms for enhanced binding effect
23. Unexpected effects of the IL-2 receptor α subunit on high affinity IL-2 receptor assembly and function detected with a mutant IL-2 analog
24. Molecular cloning of cDNA encoding human interleukin-2 receptor
25. The interleukin-2 receptor gamma chain: Its role in the multiple cytokine receptor complexes and T cell development in XSCID
26. Different interleukin 2 receptor β-chain tyrosines couple to at least two signaling pathways and synergistically mediate interleukin 2-induced proliferation
27. Several weak signals in the cytosolic and transmembrane domains of the interleukin-2 receptor-β chain allow for its efficient endocytosis
28. Endocytosis of the common cytokine receptor χ(c) chain - Identification of sequences involved in internalization and degradation
29. An α-helical signal in the cytosolic domain of the interleukin 2 receptor β chain mediates sorting towards degradation after endocytosis
30. Endocytosis of interleukin 2 receptors in human T lymphocytes: Distinct intracellular localization and fate of the receptor α, β, and γ chains
31. Receptor-mediated effects on ligand availability influence relative mitogenic potencies of epidermal growth factor and transforming growth factor α
32. Engineering epidermal growth factor for enhanced mitogenic potency
33. Increased endosomal sorting of ligand to recycling enhances potency of an interleukin-2 analog
34. Human T-cell growth factor: Purification, biochemical characterization, and interaction with a cellular receptor
35. Cell growth signal transduction is quantal
36. The interleukin-2 T-cell system: A new cell growth model
37. T-cell growth without serum
38. Molecular characterization of the signal responsible for the targeting of the interleukin 2 receptor β chain toward intracellular degradation
39. Rapid endocytosis of interleukin 2 receptors when clathrin-coated pit endocytosis is inhibited
40. Trafficking of interleukin 2 and transferrin in endosomal fractions of T lymphocytes
41. Down-regulation of interleukin-2 β and γ chains in human T lymphocytes
42. High-affinity interleukin 2 receptor α and β chains are internalized and remain associated inside the cells after interleukin 2 endocytosis
43. Receptor-mediated endocytosis of interleukin-2 in a human tumor T cell line: Degradation of interleukin-2 and evidence for the absence of recycling of interleukin receptors
44. Autocrine ligand binding to cell receptors: Mathematical analysis of competition by solution 'decoys'
45. Evidence for p55-p75 heterodimers in the absence of IL-2 from Scatchard plot analysis
46. Structural and kinetic models of interleukin-2 internalization and interaction with a multi-subunit receptor
47. Kinetics of T cell proliferation. A mathematical model and data analysis
48. Modeling the proliferative response of T cells to IL-2 and IL-4
49. Relationship between epidermal growth factor receptor occupancy and mitogenic response: Quantitative analysis using a steady-state model system
50. Epidermal growth factor binding and trafficking dynamics in fibroblasts: Relationship to cell proliferation
51. Mathematical model for the effects of epidermal growth factor receptor trafficking dynamics on fibroblast proliferation responses
52. A steady-state model for analyzing the cellular binding, internalization, and degradation of polypeptide ligands
53. A point mutation in interleukin-2 that alters ligand internalization
54. Interleukin 2 regulates its own receptors
55. The interleukin-2 receptor
56. The interleukin-2 receptor: Functional consequences of its bimolecular structure
57. Preassembly of interleukin 2 (IL-2) receptor subunits on resting Kit 225 K6 T cells and their modulation by IL-2, IL-7, and IL-15: A fluorescence resonance energy transfer study
58. The interleukin 2 receptor: The IL-2R α subunit alters the function of the IL-2R β subunit to enhance IL-2 binding and signaling by mechanisms that do not require binding of IL-2 to IL-2R α subunit
59. Interleukin-2 receptor β chain gene: Generation of three receptor forms by cloned human α and β chain cDNAs
60. Interleukin 2 receptor traffic in a murine cytolytic T cell line
61. Endocytosis of growth factor receptors
62. Signal dependent membrane protein trafficking in the endocytic pathway
63. Quantitative analysis of the endocytic system involved in hormone-induced receptor internalization
64. The endocytic rate constant: A cellular parameter for quantitating receptor-mediated endocytosis
65. Enhanced degradation of EGF receptors by a sorting nexin, SNX1
66. Intracellular receptor/ligand sorting based on endosomal retention components
67. Postendocytic trafficking of epidermal growth factor-receptor complexes is mediated through saturable and specific endosomal interactions
68. Intracellular trafficking of epidermal growth factor family ligands is directly influenced by the pH sensitivity of the receptor/ligand interaction
69. Human IgA as a heterovalent ligand: Switching from the asialoglycoprotein receptor to a secretory component during transport across the rat hepatocyte
70. The multisubunit interleukin-2 receptor
71. Controlling receptor/ligand trafficking: Effects of cellular and molecular properties on endosomal sorting
72. T cell growth factor receptors: Quantitation, specificity, and biological relevance
73. Low and high affinity cellular receptors for interleukin 2. Implications for the level of Tac antigen
74. Mutagenic analysis of a receptor contact site on interleukin-2: Preparation of an IL-2 analogue with increased potency
75. Endocytosis of the β chain of interleukin-2 receptor requires neither interleukin-2 nor the χ chain
76. Interleukin-2 (IL-2) augments transcription of the IL-2 receptor gene
77. Down-regulation of high affinity interleukin 2 receptors in a human tumor T cell line: Interleukin 2 increases the rate of surface receptor decay
78. Cohort movement of different ligands and receptors in the intracellular endocytic pathway of alveolar macrophages
79. Quantification of low-density lipoprotein and transferrin endocytic sorting in HEP2 cells using confocal microscopy
80. Growth-factor delivery in tissue engineering
81. Cellular determinants affecting the rate of cytokine depletion in cultures of human hematopoietic cells
82. Fine affinity discrimination by yeast surface display and flow cytometry
83. Introduction to stem cell biology in vitro: Threshold to the future